微芯生物(688321.SH):預計2024年淨虧損1.1億元左右
格隆匯1月17日丨微芯生物(688321.SH)公佈,(1)公司預計2024年年度實現營業收入65,784.68萬元左右,同比增長25.61%左右。(2)公司預計2024年年度實現歸屬於上市公司股東的淨利潤-11,143.37萬元左右,比上年同期減少20,027.22萬元左右,同比減少225.43%左右。(3)公司預計2024年年度實現歸屬於上市公司股東的扣除非經常性損益的淨利潤-20,290.16萬元左右,比上年同期虧損減少1,459.73萬元左右,同比虧損減少6.71%左右。
(一)本報吿期內,公司產品西達本胺和西格列他鈉銷量大幅增長,因此營業收入相應增長。(二)本報吿期內,隨着公司自身銷售團隊逐步成熟,公司與浙江海正藥業股份有限公司(以下簡稱“海正藥業”)協商一致提前終止了關於西格列他鈉片(雙洛平?)藥品的《獨佔許可及聯合營銷戰略合作協議》。海正藥業前期已支付給公司的尚未攤銷的授權許可費約6,500.00萬元和履行合同約定應支付給公司的相關週期內的臨牀試驗費用約1,700.00萬元一次性(準確金額待雙方最終確認)計入當期損益。(三)本報吿期內,公司基於臨牀試驗結果及當前臨牀診療實踐變化,決定不再遞交西奧羅尼單藥治療三線及以上小細胞肺癌的上市申請,相應將該項目開發支出餘額約9,000.00萬元全額計提資產減值準備,相應減少公司2024年年度利潤總額約9,000.00萬元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.